Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults With Class 3 Obesity.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults With Class 3 Obesity.
- Published In:
- The International journal of eating disorders, 59(2), 276-286 (2026)
- Authors:
- Maynard, Sian, Hay, Phillipa, Chimoriya, Ritesh, Acosta Reyes, Pamela, Grudzinskas, Kathy, Kormas, Nic, Piya, Milan K
- Database ID:
- RPEP-15688
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15688APA
Maynard, Sian; Hay, Phillipa; Chimoriya, Ritesh; Acosta Reyes, Pamela; Grudzinskas, Kathy; Kormas, Nic; Piya, Milan K. (2026). Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults With Class 3 Obesity.. The International journal of eating disorders, 59(2), 276-286. https://doi.org/10.1002/eat.24575
MLA
Maynard, Sian, et al. "Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults With Class 3 Obesity.." The International journal of eating disorders, 2026. https://doi.org/10.1002/eat.24575
RethinkPeptides
RethinkPeptides Research Database. "Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder..." RPEP-15688. Retrieved from https://rethinkpeptides.com/research/maynard-2026-effects-of-glp1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.